Non-Small Cell Lung Carcinoma TNM clinical staging
Item
histologically or cytologically confirmed nsclc stage iv:
boolean
C0007131 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
Non-Small Cell Lung Carcinoma TNM clinical staging | Type Any
Item
part a: nsclc stage iv (any type).
boolean
C0007131 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C0332307 (UMLS CUI [2,1])
C1552551 (UMLS CUI [2,2])
Squamous non-small cell lung cancer TNM clinical staging | Non-Squamous Non-Small Cell Lung Carcinoma TNM clinical staging
Item
part b: nsclc stage iv (squamous and nonsquamous).
boolean
C4509816 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C4324656 (UMLS CUI [2,1])
C3258246 (UMLS CUI [2,2])
Measurable Disease
Item
measurable disease at the time of study entry as defined by response evaluation criteria in solid tumors version 1.1 (recist 1.1).
boolean
C1513041 (UMLS CUI [1])
Disease Progression | Status post Chemotherapy Platinum-Based | Prior Chemotherapy Advanced disease | Prior Chemotherapy Neoplasm Metastasis | Ineligibility Second line treatment Chemotherapy | Epidermal growth factor receptor inhibitor | Anaplastic lymphoma kinase inhibitors | EGFR Activating Mutation | ALK Gene Translocation | Targeted Therapy | Neoadjuvant Therapy | Adjuvant therapy | Exception Pharmaceutical Preparations Targeting CDK4 | Exception Pharmaceutical Preparations Targeting CDK6 | Exception Necitumumab
Item
the participant must have progressed after platinum-based chemotherapy and have received a maximum of 1 other prior chemotherapy for advanced and/or metastatic disease or must be judged by the physician as ineligible for further standard second-line chemotherapy. prior treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (egfr-tki) and anaplastic lymphoma kinase (alk) inhibitors is mandatory in participants whose tumor has egfr-activating mutations or alk translocations. prior targeting agents and neoadjuvant/adjuvant therapies are permitted with the exception of cyclin-dependent kinase (cdk)4/6-targeting agents or necitumumab.
boolean
C0242656 (UMLS CUI [1])
C0231290 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C1514162 (UMLS CUI [2,3])
C1514457 (UMLS CUI [3,1])
C0679246 (UMLS CUI [3,2])
C1514457 (UMLS CUI [4,1])
C0027627 (UMLS CUI [4,2])
C1512714 (UMLS CUI [5,1])
C1710038 (UMLS CUI [5,2])
C0392920 (UMLS CUI [5,3])
C1443775 (UMLS CUI [6])
C0252409 (UMLS CUI [7,1])
C0243077 (UMLS CUI [7,2])
C2984891 (UMLS CUI [8])
C4329227 (UMLS CUI [9])
C2985566 (UMLS CUI [10])
C0600558 (UMLS CUI [11])
C0677850 (UMLS CUI [12])
C1705847 (UMLS CUI [13,1])
C0013227 (UMLS CUI [13,2])
C1521840 (UMLS CUI [13,3])
C0694873 (UMLS CUI [13,4])
C1705847 (UMLS CUI [14,1])
C0013227 (UMLS CUI [14,2])
C1521840 (UMLS CUI [14,3])
C1413287 (UMLS CUI [14,4])
C1705847 (UMLS CUI [15,1])
C2352806 (UMLS CUI [15,2])
Availability of Tumor tissue sample | Biomarker Analysis
Item
the participant has tumor tissue available for biomarker analyses.
boolean
C0470187 (UMLS CUI [1,1])
C0475358 (UMLS CUI [1,2])
C0005516 (UMLS CUI [2,1])
C0002778 (UMLS CUI [2,2])
ECOG performance status
Item
the participant has an eastern cooperative oncology group performance status score of 0-1.
boolean
C1520224 (UMLS CUI [1])
Organ function
Item
have adequate organ functions.
boolean
C0678852 (UMLS CUI [1])
Study Subject Participation Status | Investigational New Drugs | Investigational Medical Device | Pharmaceutical Preparations Targeting CDK4 | Pharmaceutical Preparations Targeting CDK6 | necitumumab
Item
the participant is currently enrolled in a clinical trial involving an investigational product or non-approved use of a drug or device. prior treatment with cdk4/6-targeting agents or necitumumab is not permitted.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C2346570 (UMLS CUI [3])
C0013227 (UMLS CUI [4,1])
C1521840 (UMLS CUI [4,2])
C0694873 (UMLS CUI [4,3])
C0013227 (UMLS CUI [5,1])
C1521840 (UMLS CUI [5,2])
C1413287 (UMLS CUI [5,3])
C2352806 (UMLS CUI [6])
Comorbidity Systemic Serious | Heart Disease
Item
have a serious concomitant systemic disorder or significant cardiac disease.
boolean
C0009488 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0205404 (UMLS CUI [1,3])
C0018799 (UMLS CUI [2])
Major surgery | Therapy, Investigational
Item
the participant has undergone major surgery or received any investigational therapy in the 30-days prior to study enrollment.
boolean
C0679637 (UMLS CUI [1])
C0949266 (UMLS CUI [2])
Radiotherapy to thorax
Item
the participant has undergone chest irradiation within 4 weeks prior to receiving study treatment.
boolean
C4038705 (UMLS CUI [1])
Metastatic malignant neoplasm to brain Symptomatic
Item
the participant has brain metastases that are symptomatic.
boolean
C0220650 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
Arterial thromboembolism | Venous Thromboembolism
Item
history of arterial or venous thromboembolism within 3 months prior to study enrollment. participants with a history of venous thromboembolism beyond 3 months prior to study enrollment can be enrolled if they are appropriately treated with low molecular weight heparin.
boolean
C3544094 (UMLS CUI [1])
C1861172 (UMLS CUI [2])
Communicable Disease
Item
the participant has any ongoing or active infection.
boolean
C0009450 (UMLS CUI [1])
Hypersensitivity Therapeutic procedure Component | Allergic Reaction Therapeutic procedure Component | Hypersensitivity Necitumumab Ingredient | Allergic Reaction Necitumumab Ingredient | Hypersensitivity Abemaciclib Ingredient | Allergic Reaction Abemaciclib Ingredient | Medical contraindication Therapeutic procedure
Item
the participant has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab or abemaciclib, or any other contraindication to one of the administered treatments.
boolean
C0020517 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C1705248 (UMLS CUI [1,3])
C1527304 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C1705248 (UMLS CUI [2,3])
C0020517 (UMLS CUI [3,1])
C2352806 (UMLS CUI [3,2])
C1550600 (UMLS CUI [3,3])
C1527304 (UMLS CUI [4,1])
C2352806 (UMLS CUI [4,2])
C1550600 (UMLS CUI [4,3])
C0020517 (UMLS CUI [5,1])
C3852841 (UMLS CUI [5,2])
C1550600 (UMLS CUI [5,3])
C1527304 (UMLS CUI [6,1])
C3852841 (UMLS CUI [6,2])
C1550600 (UMLS CUI [6,3])
C1301624 (UMLS CUI [7,1])
C0087111 (UMLS CUI [7,2])
Pregnancy | Breast Feeding
Item
the participant is pregnant or breastfeeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Cancer Other | Exception Disease Free Duration | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated | Exception Carcinoma in situ of uterine cervix | Exception Prostate carcinoma | Exception Malignant neoplasm of urinary bladder
Item
the participant has a concurrent active malignancy. previous history of malignancy is permitted, provided that the participant has been free of disease for ≥3 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, preinvasive carcinoma of the cervix, or any cancers that in the judgment of the investigator and sponsor may not affect the interpretation of results (for example, prostate, bladder).
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0012634 (UMLS CUI [2,2])
C0332296 (UMLS CUI [2,3])
C0449238 (UMLS CUI [2,4])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0553723 (UMLS CUI [4,2])
C1522326 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0851140 (UMLS CUI [5,2])
C1705847 (UMLS CUI [6,1])
C0600139 (UMLS CUI [6,2])
C1705847 (UMLS CUI [7,1])
C0005684 (UMLS CUI [7,2])
Lung Disease, Interstitial
Item
history of interstitial lung disease.
boolean
C0206062 (UMLS CUI [1])